Lercan

Lercanidipine Hydrochloride, the active ingredient in Lercan, is a calcium channel blocker presented as an oral tablet for oral use. It treats essential hypertension in adult patients.

GNH USA supplies Lercan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercan (lercanidipine hydrochloride) is indicated for conditions involving elevated blood pressure within the cardiovascular system.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: reduces elevated systolic pressure, improving cardiovascular risk. - High blood pressure: provides sustained vasodilation to achieve target blood pressure goals.

Lercan may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, especially after standing. - Palpitations: awareness of heartbeats. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Elevated liver enzymes: signs of hepatic stress. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lercan, several safety considerations should be observed.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: use with caution; dose adjustment may be needed. - Elderly patients: start at low dose and titrate slowly. - Concomitant antihypertensives: watch for additive hypotensive effects. - CYP3A4 inhibitors: avoid strong inhibitors that may increase drug levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercan can interact with other medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations. - Grapefruit juice: can increase drug exposure and risk of hypotension. - Other potent vasodilators: may cause additive blood pressure lowering.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: observe for excessive bradycardia or hypotension.